Summary
Zoetis Inc. reported solid performance for the third quarter and the first nine months of 2022, demonstrating resilience despite global economic uncertainties. For the three months ended September 30, 2022, revenue increased slightly to $2,002 million, up 1% from the prior year, driven by operational growth partially offset by unfavorable foreign exchange. Net income attributable to Zoetis Inc. was $529 million, a decrease of 4% compared to the prior year, impacted by a higher effective tax rate and increased cost of sales as a percentage of revenue. However, on an operational basis, revenue grew by 5% for the quarter and 7% for the nine-month period, indicating underlying business strength. For the nine months ended September 30, 2022, total revenue reached $6,040 million, a 4% increase year-over-year. The company highlighted strong performance in companion animal products, particularly driven by new product volume and key dermatology brands. While livestock products saw a decrease, the overall diversified portfolio provided stability. The company's strategic focus on innovation and market expansion continues, supported by prudent management of expenses and a solid balance sheet, positioning Zoetis to navigate ongoing market challenges.
Financial Highlights
51 data points| Revenue | $2.00B |
| Cost of Revenue | $607.00M |
| Gross Profit | $1.40B |
| SG&A Expenses | $501.00M |
| Interest Expense | $53.00M |
| Net Income | $528.00M |
| EPS (Basic) | $1.13 |
| EPS (Diluted) | $1.13 |
| Shares Outstanding (Basic) | 467.80M |
| Shares Outstanding (Diluted) | 469.10M |
Key Highlights
- 1Total revenue for the third quarter of 2022 was $2,002 million, a 1% increase year-over-year.
- 2Operational revenue growth was 5% for the quarter and 7% for the first nine months of 2022, excluding foreign exchange impacts.
- 3Net income attributable to Zoetis Inc. for the third quarter was $529 million, a decrease of 4% compared to the prior year, impacted by a higher effective tax rate.
- 4Cost of sales as a percentage of revenue increased to 30.3% in Q3 2022 from 29.4% in Q3 2021, attributed to unfavorable manufacturing costs, foreign exchange, and higher freight costs.
- 5Companion animal products showed strong growth, particularly in the U.S. and internationally, driven by parasiticides and dermatology products.
- 6The company maintained a strong liquidity position with $2,507 million in cash and cash equivalents as of September 30, 2022.
- 7Zoetis continued to invest in R&D, with expenses increasing by 2% for the quarter and 6% for the nine-month period.